TIGIT blows up in a trial that always looked risky
Keyvibe-008 is halted for futility, an outcome that might have been foreseen in 2022.
The month ahead: August’s remaining events
Following its odronextamab knockback, Regeneron now faces a delay to linvoseltamab.
Blood cancer gene therapies enter the clinic
First-in-human trial initiations feature Interius, Umoja and Vironexis.
Claudin18.2 expression clouds Elevation's big reveal
Western data on EO-3021 fail to live up to the billing of a Chinese trial.
Nuvalent’s next battleground is HER2
NVL-330 features among the latest crop of industry projects newly into human trials.
